cardiovascular disease

Roche pens $2B deal with Atavistik to discover new CVRM drugs

Roche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.

James Waldron Sep 24, 2026 8:35am

Boehringer adds $250M to Variant pact via cardio expansion

Sep 23, 2026 8:55am

Prospects for Novo’s CKD program narrow as ph. 3 trials scrapped

Sep 7, 2026 8:39am

Novo left praying to Artemis and Hermes as CKD trial flops

Jul 31, 2026 8:57am

Scribe notes IPO plan to push lipid-lowering meds through clinic

Jul 6, 2026 7:54am

UPDATED: Kardigan buttons up $400M upsized IPO for phase 3 push

Jun 18, 2026 7:28am